A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
NCT ID: NCT04440735
Last Updated: 2025-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
125 participants
INTERVENTIONAL
2020-10-07
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Part 2: Preliminary efficacy assessment of DSP107 in combination with atezolizumab in second or third line treatment of non small cell lung cancer. Preliminary efficacy assessment of DSP107 as a single agent or in combination with atezolizumab in third line treatment of colorectal cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
NCT03416335
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279
A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
NCT03416816
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
NCT02108652
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
NCT04244552
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Part 1 will involve DSP107 monotherapy dose escalation in subjects with advanced solid tumors that are not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit. Additional dose finding cohorts will be enrolled to establish a safe dose of DSP107 when given in combination with atezolizumab.
Part 2 will comprise two expansion cohorts:
A) Expansion cohort A consisting of one treatment arm in which subjects will be treated with DSP107 in combination with atezolizumab. This expansion cohort will enroll subjects with non small cell lung cancer who have progressed following no more than 2 lines of prior systemic treatment including treatment with PD-1 or PD-L1 targeting agents.
B) Expansion cohort B consisting of two treatment arms in which subjects will be treated either with DSP107 monotherapy or DSP107 in combination with atezolizumab. This expansion cohort will enroll subjects with colorectal cancer who have progressed following two previous lines of therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
Up to 3 additional dose finding cohorts will be enrolled in parallel to the monotherapy dose escalation to establish a safe dose of DSP107 when given in combination with atezolizumab. These dose-finding combination arms will start at least one dose level below a DSP107 monotherapy dose that has already been deemed safe.
Part 2 will comprise 2 expansion cohorts:
Expansion cohort A will involve enrollment of patients in a single arm receiving DSP107 in combination with atezolizumab.
Expansion cohort B will involve enrollment of patients randomized to receive either DSP107 monotherapy or DSP107 in combination with atezolizumab.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DSP107 monotherapy in advanced solid tumors
DSP107 will be administered by intravenous infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle for up to 12 treatment cycles. Starting dose will be 0.01 mg/kg and maximum dose will not exceed 10 mg/kg.
DSP107
DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
DSP107 in combination with atezolizumab in advanced solid tumors
DSP107 will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion. The study will include up to 12 treatment cycles.
DSP107
DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
Atezolizumab
Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
DSP107 in combination with atezolizumab in non-small cell lung cancer
DSP107 10mg/kg will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion. The study will include up to 12 treatment cycles.
DSP107
DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
Atezolizumab
Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
DSP107 monotherapy in colorectal cancer
DSP107 10mg/kg will be administered by intravenous infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle for up to 12 treatment cycles..
DSP107
DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
DSP107 in combination with atezolizumab in colorectal cancer
DSP107 10mg/kg will be administered by IV infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle. Subjects will receive atezolizumab 1200 mg by intravenous infusion over 30 mins (first infusion over 1 hour) on Day 1 of every treatment cycle. DSP107 infusion will commence 1 hour following completion of atezolizumab infusion. The study will include up to 12 treatment cycles.
DSP107
DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
Atezolizumab
Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DSP107
DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
Atezolizumab
Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject must have measurable disease per RECIST version 1.1
* Part 1:
o Histologically confirmed advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit or subject is intolerant or has refused available therapies
* Part 2, Expansion Cohort A:
* Histologically confirmed, inoperable non-small cell lung cancer (Stage 3b or Stage 4). Squamous and non-squamous histologies are both acceptable
* Wildtype for actionable oncogenic driver mutations (e.g., ALK, EGFR, ROS1, RET, NTRK). Driver mutations for KRAS, BRAF and c-METex14skip will be allowed.
* Received no more than 2 lines of prior systemic treatment, including anti PD-1 or anti PD-L1 therapeutic agent ± chemotherapy. Targeted therapies for KRAS, BRAF and c-METex14skip will not be counted towards the previous lines of therapy.
* Part 2, Expansion Cohort B:
* Histologically confirmed, inoperable microsatellite stable colorectal carcinoma (Stage 3b or Stage 4)
* Received two previous lines of therapy including standard chemotherapy and/or targeted antibodies
Exclusion Criteria
* Central nervous system (CNS) metastases
* Life-threatening (grade 4) immune-mediated adverse event related to prior immunotherapy
* Immune-mediated adverse reaction that required discontinuation of prior immunotherapy
* Past or current history of autoimmune disease or immune deficiency
* History of autoimmune hemolytic anemia or autoimmune thrombocytopenia
* History of hematological malignancy
* History of organ or stem cell transplantation
* Clinically significant liver disease, including alcoholic hepatitis, cirrhosis, fatty liver disease and inherited liver disease
* Previously treatment with CAR-T cells
* Treatment with systemic immunosuppressive medication within 2 weeks prior to first dose of study treatment
* Received live, attenuated vaccine within 4 weeks prior to first dose of study treatment
* Treatment with systemic immunostimulatory agents within 4 weeks prior to first dose of study treatment
* Treatment with atezolizumab, any CD47/SIRPα targeting agent or immune agonists (e.g., anti-CD137, anti-CD40, anti-OX40)
* Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product
* Clinically significant abnormal laboratory safety tests
* Detection of anti DSP107 antibodies at screening
* History of HIV infection or active Hepatitis B or C infection
* Pregnant or breast feeding or planning to become pregnant while enrolled in the study
* History or evidence of any other clinically unstable/uncontrolled disorder, condition, or disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kahr Medical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jason Luke, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh
Anwaar Saeed, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh
Jun Zhang, MD
Role: PRINCIPAL_INVESTIGATOR
KUMC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Moores Cancer Center, UCSD
La Jolla, California, United States
University of Colorado Hospital, Anschutz Cancer Pavilion (ACP)
Aurora, Colorado, United States
Florida Cancer Specialists
Lake Mary, Florida, United States
Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
KUCC / KUMCRI University of Kansas Cancer Center
Kansas City, Kansas, United States
SKCC-Sidney Kimmel Cancer Center Thomas Jefferson University
Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DSP107_001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.